Literature DB >> 4039634

High-dose intravenous metoclopramide and intermittent intramuscular prochlorperazine and diazepam in the management of emesis induced by cis-dichlorodiammineplatinum.

D M Luesley, P B Terry, K K Chan.   

Abstract

Intravenous metoclopramide and IM prochlorperazine and diazepam were compared in the management of vomiting occurring during treatment with cis-dichlorodiammineplatinum (cis-platinum). A total of 104 cycles in 30 patients were evaluated. Twenty-two patients took part in a cross-over study in which emetic profiles for each patient managed with each anti-emetic schedule were compared. In all, 44 cycles of treatment in 22 patients were evaluated as part of a cross-over study. No significant difference in emetic control was observed between the two anti-emetic regimens. The side-effects observed using IV metoclopramide included extrapyramidal phenomena (19%) and flushing attacks (16%).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039634     DOI: 10.1007/bf00258127

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

Authors:  C Morran; D C Smith; D A Anderson; C S McArdle
Journal:  Br Med J       Date:  1979-05-19

2.  Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways.

Authors:  A L Harris
Journal:  Lancet       Date:  1982-03-27       Impact factor: 79.321

3.  Antiemetics: neurotransmitter receptor binding predicts therapeutic actions.

Authors:  S J Peroutka; S H Snyder
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

Review 4.  Platinum nephrotoxicity.

Authors:  N E Madias; J T Harrington
Journal:  Am J Med       Date:  1978-08       Impact factor: 4.965

5.  Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy.

Authors:  H W Bruckner; C J Cohen; R C Wallach; B Kabakow; G Deppe; E M Greenspan; S B Gusberg; J F Holland
Journal:  Cancer Treat Rep       Date:  1978-04

6.  The metabolism of cis-dichlorodiammineplatinum (II): distribution, clearance, and toxicity.

Authors:  L D Lagasse; R G Pretorius; E S Petrilli; L C Ford; J Hoeschele; C Kean
Journal:  Am J Obstet Gynecol       Date:  1981-04-01       Impact factor: 8.661

7.  Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary.

Authors:  G H Barker; E Wiltshaw
Journal:  Br J Obstet Gynaecol       Date:  1981-12

8.  Single-agent cis-platinum therapy for advanced ovarian cancer.

Authors:  D M Gershenson; J T Wharton; J Herson; C L Edwards; F N Rutledge
Journal:  Obstet Gynecol       Date:  1981-10       Impact factor: 7.661

9.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.